Novartis has cut six early-stage cancer candidates while adding two to refine its oncology strategy. CEO Vas Narasimhan emphasized ongoing investment in the early-stage pipeline and a focus on deals under $2 billion.

PrimeGen is set to go public via a SPAC deal valued at $1.5 billion, providing necessary capital to advance its pre-clinical triple-activated mesenchymal stem cell pipeline. This move positions PrimeGen to accelerate its clinical development efforts.

Eli Lilly has decided to discontinue three therapies, including a gene therapy for dementia acquired through its $1.04 billion purchase of Prevail Therapeutics. This move aligns with Lilly's strategy to focus on its GLP-1 pipeline.

Emerging platforms like circular and logic circuit RNA are expanding therapeutic possibilities in the post-COVID landscape, according to insights from industry leaders at Circio and Strand Therapeutics. This discussion highlights the innovative approaches shaping the future of RNA technology.

Pharma Times discusses the evolving landscape of customer relationships in biopharma, emphasizing the need for enhanced engagement strategies. The article highlights innovative approaches to connect with patients and stakeholders.

Pharma Times highlights the shift towards patient-centric oncology trials, emphasizing the use of data-driven insights to enhance cancer care. This approach aims to improve patient outcomes by integrating their experiences and preferences into trial designs.

Biopharma companies are increasingly open to hiring remote workers, as highlighted in the latest BioSpace employment outlook report. This shift indicates a broader trend towards flexible recruitment strategies, allowing access to a wider talent pool.

Regulatory professionals face significant challenges, particularly with the recent upheaval at the FDA and the need to adapt to new artificial intelligence guidance. Experts emphasize the importance of effective collaboration with regulators to navigate these complexities.

Canada's federal government has introduced Bill S-5, the Connected Care for Canadians Act, aimed at standardizing health data sharing among physicians and patients. This legislation addresses the challenges of accessing and sharing medical records, which can impact patient care.

Sarepta Therapeutics faces increasing investor skepticism following patient deaths linked to its gene therapies, prompting concerns about its competitive edge. As doubts grow, patients may seek alternatives, impacting Sarepta's market position.

The FDA has placed clinical holds on RegenXBio's investigational gene therapies RGX-111 and another for rare neurodevelopmental disorders, including mucopolysaccharidosis type I (Hurler syndrome). This decision follows the discovery of a neoplasm in a trial participant, impacting ongoing studies.

New immunotherapy combinations for relapsed or refractory follicular lymphoma show promising efficacy in recent phase III trials. The addition of tafasitamab or epcoritamab to lenalidomide–rituximab (R2) offers potential new treatment options for patients.

The CDC has launched the SUDORS Dashboard, providing detailed data on unintentional and undetermined intent drug overdose deaths. This resource aims to enhance understanding and inform policy decisions regarding drug-related fatalities.

The CDC has issued guidance on the emergency use of doxycycline to prevent anthrax exposure. This policy aims to enhance preparedness against potential bioterrorism threats.

Generate Biomedicines Inc. has filed for an initial public offering, reflecting strong investor interest in the biotech sector. The company is focused on developing treatments for severe asthma and chronic obstructive pulmonary disease.